Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis

G. Kesava Reddy, Richard J. Gralla, Paul J. Hesketh

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Despite significant advances in supportive care in oncology, many patients with cancer still experience chemotherapy-induced nausea and vomiting (CINV). Historically, there were only 3 neurotransmitter receptors (dopamine D2, cannabinoid-1, and 5-hydroxytryptamine-3) that were the known targets for antiemetic therapy. Major advances in the management of chemotherapy-induced emesis were seen with the introduction of 5-hydroxytryptamine-3 receptor antagonists, which include palonosetron, ondansetron, tropisetron, dolasetron, and granisetron. However, recently, selective inhibitors of substance P have shown promising activity in the management of CINV in patients with cancer. Substance P mediates a number of biologic effects by binding to a specific neuroreceptor, neurokinin-1 (NK-1). Among the NK-1 receptor antagonists, aprepitant has been approved for the treatment of CINV. Currently, several other NK-1 receptor antagonists, including casopitant, vestipitant, netupitant, and SCH619734, are undergoing clinical evaluation for the prevention of CINV in patients with a variety of malignancies. The clinical potential of these novel NK-1 receptor antagonists and their respective ongoing clinical trials for the management of chemotherapy-induced emesis are discussed briefly herein.

Original languageEnglish (US)
Pages (from-to)140-142
Number of pages3
JournalSupportive Cancer Therapy
Volume3
Issue number3
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Antiemetics
Vomiting
Neurokinin-1 Receptor Antagonists
Drug Therapy
Nausea
tropisetron
aprepitant
Substance P
Therapeutics
Granisetron
Receptors, Serotonin, 5-HT3
Ondansetron
Neoplasms
Neurotransmitter Receptor
Cannabinoids
Sensory Receptor Cells
Dopamine
Serotonin
Clinical Trials

Keywords

  • 5-Hydroxytryptamine-3 receptor antagonists
  • Aprepitant
  • Casopitant
  • Nausea
  • Vomiting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology

Cite this

Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. / Reddy, G. Kesava; Gralla, Richard J.; Hesketh, Paul J.

In: Supportive Cancer Therapy, Vol. 3, No. 3, 04.2006, p. 140-142.

Research output: Contribution to journalArticle

Reddy, G. Kesava ; Gralla, Richard J. ; Hesketh, Paul J. / Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. In: Supportive Cancer Therapy. 2006 ; Vol. 3, No. 3. pp. 140-142.
@article{f50ba009ddf84c5b9f833a81520bf9f0,
title = "Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis",
abstract = "Despite significant advances in supportive care in oncology, many patients with cancer still experience chemotherapy-induced nausea and vomiting (CINV). Historically, there were only 3 neurotransmitter receptors (dopamine D2, cannabinoid-1, and 5-hydroxytryptamine-3) that were the known targets for antiemetic therapy. Major advances in the management of chemotherapy-induced emesis were seen with the introduction of 5-hydroxytryptamine-3 receptor antagonists, which include palonosetron, ondansetron, tropisetron, dolasetron, and granisetron. However, recently, selective inhibitors of substance P have shown promising activity in the management of CINV in patients with cancer. Substance P mediates a number of biologic effects by binding to a specific neuroreceptor, neurokinin-1 (NK-1). Among the NK-1 receptor antagonists, aprepitant has been approved for the treatment of CINV. Currently, several other NK-1 receptor antagonists, including casopitant, vestipitant, netupitant, and SCH619734, are undergoing clinical evaluation for the prevention of CINV in patients with a variety of malignancies. The clinical potential of these novel NK-1 receptor antagonists and their respective ongoing clinical trials for the management of chemotherapy-induced emesis are discussed briefly herein.",
keywords = "5-Hydroxytryptamine-3 receptor antagonists, Aprepitant, Casopitant, Nausea, Vomiting",
author = "Reddy, {G. Kesava} and Gralla, {Richard J.} and Hesketh, {Paul J.}",
year = "2006",
month = "4",
doi = "10.3816/SCT.2006.n.011",
language = "English (US)",
volume = "3",
pages = "140--142",
journal = "Supportive Cancer Therapy",
issn = "1543-2912",
publisher = "Cancer Information Group, LP",
number = "3",

}

TY - JOUR

T1 - Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis

AU - Reddy, G. Kesava

AU - Gralla, Richard J.

AU - Hesketh, Paul J.

PY - 2006/4

Y1 - 2006/4

N2 - Despite significant advances in supportive care in oncology, many patients with cancer still experience chemotherapy-induced nausea and vomiting (CINV). Historically, there were only 3 neurotransmitter receptors (dopamine D2, cannabinoid-1, and 5-hydroxytryptamine-3) that were the known targets for antiemetic therapy. Major advances in the management of chemotherapy-induced emesis were seen with the introduction of 5-hydroxytryptamine-3 receptor antagonists, which include palonosetron, ondansetron, tropisetron, dolasetron, and granisetron. However, recently, selective inhibitors of substance P have shown promising activity in the management of CINV in patients with cancer. Substance P mediates a number of biologic effects by binding to a specific neuroreceptor, neurokinin-1 (NK-1). Among the NK-1 receptor antagonists, aprepitant has been approved for the treatment of CINV. Currently, several other NK-1 receptor antagonists, including casopitant, vestipitant, netupitant, and SCH619734, are undergoing clinical evaluation for the prevention of CINV in patients with a variety of malignancies. The clinical potential of these novel NK-1 receptor antagonists and their respective ongoing clinical trials for the management of chemotherapy-induced emesis are discussed briefly herein.

AB - Despite significant advances in supportive care in oncology, many patients with cancer still experience chemotherapy-induced nausea and vomiting (CINV). Historically, there were only 3 neurotransmitter receptors (dopamine D2, cannabinoid-1, and 5-hydroxytryptamine-3) that were the known targets for antiemetic therapy. Major advances in the management of chemotherapy-induced emesis were seen with the introduction of 5-hydroxytryptamine-3 receptor antagonists, which include palonosetron, ondansetron, tropisetron, dolasetron, and granisetron. However, recently, selective inhibitors of substance P have shown promising activity in the management of CINV in patients with cancer. Substance P mediates a number of biologic effects by binding to a specific neuroreceptor, neurokinin-1 (NK-1). Among the NK-1 receptor antagonists, aprepitant has been approved for the treatment of CINV. Currently, several other NK-1 receptor antagonists, including casopitant, vestipitant, netupitant, and SCH619734, are undergoing clinical evaluation for the prevention of CINV in patients with a variety of malignancies. The clinical potential of these novel NK-1 receptor antagonists and their respective ongoing clinical trials for the management of chemotherapy-induced emesis are discussed briefly herein.

KW - 5-Hydroxytryptamine-3 receptor antagonists

KW - Aprepitant

KW - Casopitant

KW - Nausea

KW - Vomiting

UR - http://www.scopus.com/inward/record.url?scp=33745782052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745782052&partnerID=8YFLogxK

U2 - 10.3816/SCT.2006.n.011

DO - 10.3816/SCT.2006.n.011

M3 - Article

C2 - 18632487

AN - SCOPUS:33745782052

VL - 3

SP - 140

EP - 142

JO - Supportive Cancer Therapy

JF - Supportive Cancer Therapy

SN - 1543-2912

IS - 3

ER -